IQVIA (NYSE:IQV) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a research note released on Wednesday morning.

Other research analysts have also recently issued research reports about the stock. Truist Financial cut their target price on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Morgan Stanley cut their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. UBS Group upped their price target on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Robert W. Baird cut their price objective on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Trading Up 2.1 %

NYSE IQV opened at $201.82 on Wednesday. The stock has a 50-day moving average of $222.67 and a 200-day moving average of $227.16. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The firm has a market cap of $36.63 billion, a PE ratio of 26.49, a price-to-earnings-growth ratio of 2.03 and a beta of 1.51.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently made changes to their positions in IQV. Unigestion Holding SA bought a new stake in shares of IQVIA in the 3rd quarter worth $521,000. TD Private Client Wealth LLC increased its holdings in IQVIA by 8.4% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,031 shares of the medical research company’s stock worth $244,000 after buying an additional 80 shares in the last quarter. Toronto Dominion Bank raised its position in IQVIA by 11.3% in the 3rd quarter. Toronto Dominion Bank now owns 60,416 shares of the medical research company’s stock worth $14,317,000 after buying an additional 6,149 shares during the last quarter. Neo Ivy Capital Management bought a new position in IQVIA during the 3rd quarter valued at about $470,000. Finally, Brown Financial Advisors boosted its holdings in shares of IQVIA by 13.0% during the 3rd quarter. Brown Financial Advisors now owns 3,432 shares of the medical research company’s stock valued at $813,000 after acquiring an additional 396 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.